TP53 and neoplasm: Therefore, Ishizaki et al. constructed an Lm-based vaccine targeting human p53, LmddA-LLO-p53, and assessed its anti-tumor efficacy against 4T1 tumor cells stably expressing mutant human p53 (4T1p53) in tolerant human p53 knock-in (Hupki) mice (Ishizaki et al., 2010).